Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B

Turkish Journal of Gastroenterology

Volumn 23, Issue 3, 2012, Pages 247-252

  Doǧan, Ümit Bilge ^a   Kara, Banu ^a   Gümürdülü, Yüksel ^b   Soylu, Aliye ^c   Akin, Mustafa Salih ^a  

^a Adana Numune Training and Research Hospital   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

^c Bakirköy Sadi Konuk Training and Research Hospital   (Turkey)

Author keywords

Chronic hepatitis B; Entecavir; Tenofovir

Indexed keywords

DNA; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; NUCLEOSIDE ANALOG; TENOFOVIR;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HEPATITIS VIRUS; HOSPITAL; HUMAN; LABORATORY; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; SIDE EFFECT; TREATMENT DURATION;

ADENINE; ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866488720     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.4318/tjg.2012.0380     Document Type: Article

References (29)

1. Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Drugs 2009; 18: 1655-66.
2. Friede MW, Piratvisuth T, Lau GKK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg positive chronic hepatitis B. Hepatology 2008; 47: 428-34.
3. Sonneveld MJ, Rijckborst V, Boucher CAB, et al. Prediction of sustained response to peginterferon alfa 2-b for HBe-Ag positive chronic hepatitis B using on treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-7.
4. Ayoub SB, Keefe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2008; 28: 167-77.
5. Keefe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936-62.
6. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.
7. Liaw YF, Gane E, Leung N, et al. 2 year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-95.
8. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-29.
9. Honkoop P, De Man RA. Entacavir. A potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs 2003; 12: 683-8.
10. Tenny DJ, Pokornowsky KA, Rose RE, et al. Entecavir at five years shows long term maintenance of high genetic barrier to hepatitis B virus resistance (abstract). Hepatol Int 2008; 2: A88-9.
11. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for tthe treatment of lamivudine resistant hepatitis B mutants. Hepatology 2000; 32: 129-34.
12. Hadziyannis SJ, Tassopoulos NC, Hethcote EJ, et al. Long therm therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis B up to 5 years. Gastroenterology 2006; 131: 1743-51.
13. Jenh AM, Thio CL, Pham PA. Tenofovir for the treatment of hepatitis B virus. Pharmacotherapy 2009; 29: 1212-27.
14. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
15. Chen CJ, Yang HI, Su J, et al. REVEAL HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus level. JAMA 2006; 295: 65-73.
16. Iloeje UH, Yang HI, Su J, et al. Risk evaluation of viral load elevation and associated liver disease/cancer in HBV (The REVEAL HBV) study group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
17. Rejinders JGP, Pas SD, Schutten M, et al. Entacavir shows limited efficacy in HBeAg positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 2009; 50: 674-83.
18. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
19. Ren FY, Piao DM, Piao XX. A one year trial of entecavir treatment in patients with HBeAg positive chronic hepatitis B. World J Gastroenterol 2007; 13: 4264-7.
20. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
21. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
22. Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in HBeAg positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009; 49: 72-9.
23. Shim JH, Suh DJ, Kim KM, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009; 50: 1064-71.
24. Kim HJ, Park JH, Park DII, et al. Rescue therapy for lamivudine resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010; 25: 1374-80.
25. Marcellin P, Heathcote J, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
26. Van Bömmel F, Zöllner B, Sarrazin C, et al. Tenofovir for patients with lamivudine resistant hepatitis B virus infection and high HBV-DNA level during adefovir therapy. Hepatology 2006; 44: 318-25.
27. Van Bömmel F, Wünsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine resistant hepatitis B virus infection. Hepatology 2004; 40: 1421-5.
28. Van Bömmel F, de Man RA, Wedemeyer H, et al. Long term efficacy of tenofovir monotherapy for hepatitis B virus monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
29. Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos( t)ides for treatment of nucleos(t)ide naive patients with chronic hepatitis B. Value Health 2010; 13: 934-45.